Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10744639 | 0.78 | IDH1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL5668391 | 0.78 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL11085212 | 0.78 | MAPT (0.33) | ALDH1A1CYP3A4 | |
| SCHEMBL6912656 | 0.78 | C5AR1 (0.33) | TDP1 | |
| SCHEMBL10688042 | 0.78 | — | — | |
| SCHEMBL10400626 | 0.77 | CYP3A4 (0.31) | CYP3A4TDP1 | |
| SCHEMBL4280773 | 0.77 | ALDH1A1 (0.33) | ALDH1A1CYP3A4TDP1 | |
| SCHEMBL2326868 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL2469938 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL9958346 | 0.75 | TP53 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119612552-A | Preparation method of hollow Prussian blue positive electrode material | 浙江山高新能源有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-118165145-A | Synthesis method of low molecular weight vinyl-terminated fluorine-containing polymer | 沈阳化工大学 | 2024-06-11 | — | — | CN | claimed |
| CN-109021701-A | The preparation method of quantum dot ink and light emitting diode with quantum dots | TCL集团股份有限公司 | 2018-12-18 | — | — | CN | claimed |
| CN-108840881-A | A kind of tetra- substituted benzene of 1,2,3,5- and its synthetic method of the silicon substrate containing 3- | 重庆大学 | 2018-11-20 | — | — | CN | claimed |
| CN-108299490-A | A kind of tetra- substituted benzenes of 1,2,3,5- and its synthetic method of the silicon substrate containing 5- | 重庆大学 | 2018-07-20 | — | — | CN | claimed |
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | claimed |
| EP-1874770-B1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-09 | — | — | EP | claimed |
| EP-1874770-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | Novartis Pharma AG (CH) | 2008-01-09 | — | — | EP | claimed |
| WO-2006108640-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | claimed |
| EP-0853108-B1 | Ink jet ink compositions and processes for high resolution and high speed printing | XEROX CORP (US) | 2002-08-21 | — | — | EP | claimed |
| EP-1107964-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2001-06-20 | — | — | EP | claimed |
| WO-2000009495-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2000-02-24 | — | — | WO | claimed |
| US-5851274-A | Ink jet ink compositions and processes for high resolution and high speed printing | XEROX CORPORATION (US) | 1998-12-22 | — | — | US | claimed |
| EP-0853108-A1 | Ink jet ink compositions and processes for high resolution and high speed printing | XEROX CORPORATION (US) | 1998-07-15 | — | — | EP | claimed |
| US-6424364-B1 | — | — | None | — | — | US | disclosed |
| JP-9048853-A | — | — | None | — | — | JP | disclosed |
| CN-119612552-A | Preparation method of hollow Prussian blue positive electrode material | 浙江山高新能源有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-4886793-A | PENICILLINS; HUMANS OR ANIMALS | FARMITALIA CARLO ERBA, S.R.L. (IT) | 1989-12-12 | — | — | US | disclosed |
| EP-0236880-A2 | Penem derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1987-09-16 | — | — | EP | disclosed |
| US-4403054-A | SULFOXIDE COMPOUND OR SULFINYL-CONTAINING POLYMER | GENERAL ELECTRIC COMPANY (US) | 1983-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | MAP3K10, MAP3K20, MAP3K9 | ALDH1A1 3213/4885TSHR 2185/4885CYP3A4 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.